A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone or Co-administered With an Adjuvanted Vaccine Against Influenza in Adults Aged 65 Years and Above

NCT05568797 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1045

Enrollment

INDUSTRY

Sponsor class

Conditions

Respiratory Syncytial Virus Infections

Interventions

BIOLOGICAL: RSVPreF3 OA vaccine
BIOLOGICAL: FLU vaccine

Sponsor

GlaxoSmithKline